Shikonin Promotes Apoptosis in Multiple Myeloma Cells Through the PKM2 ‐ AMPK ‐ PGC1α Metabolic Axis
Journal of Clinical Laboratory Analysis · 2026
DOI: 10.1002/jcla.70384 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, 2026. Verfasst von Fengping Peng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Naphthoquinones, Apoptosis, Multiple Myeloma, AMP-Activated Protein Kinases. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tianjin Education Commission Research Project.
Abstract (Originalsprache)
Background
Multiple myeloma (MM) is an incurable plasma malignancy. Pyruvate kinase M2 (PKM2), a rate‐limiting enzyme in glycolysis, is involved in the metabolic reprogramming of tumors. Shikonin, a natural compound, exhibits anticancer potential. However, whether modulating PKM2 with shikonin can be used as an adjuvant chemotherapeutic strategy for MM remains to be elucidated. We explored the effects of shikonin on the metabolic pathways in MM cells.
Methods
Apoptosis, reactive oxygen species (ROS) production, and cell cycle progression in MM cells treated with shikonin were analyzed using flow cytometry. Shikonin‐treated MM cells were sent for Metabolomics by RNA sequencing and LC–MS/MS metabolomics. The involved signaling pathways were validated using western blotting.
Results
The coMMpass cohort analysis has indicated that high PKM2 expression was related to poor survival of MM cells. Shikonin induced dose‐dependently apoptosis, elevated ROS levels, and cell cycle arrest in G1 phase in MM cells. Multi‐omics analysis revealed 2043 differentially expressed genes and 93 altered metabolites in shikonin‐treated MM cells. Shikonin downregulated the expression of PKM2 and therefore reduced pyruvate/AMP levels and impaired glycolysis. Integrated omics analysis identified AMPK signaling as the common enriched pathway. WB confirmed that shikonin suppressed the expression of PKM2 and GLUT4 and activated the expression of P‐AMPK/PGC1α, indicating the dysregulation of the PKM2‐AMPK‐PGC1α axis.
Conclusion
Shikonin exerts anti‐tumor effects in MM cells by inhibiting PKM2 expression, disrupting glycolytic flux, activating AMPK/PGC1α‐mediated metabolic stress, and triggering the apoptosis process. Inhibition of PKM2 with shikonin is a promising metabolic intervention strategy for MM treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
- Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin, China.
- Tianjin Institute of Hematology, Tianjin, China.
- College of Science and Technology, Hebei Agricultural University, Baoding, China.
ORCID-Profile: Yu Gao, Ziqi Zhang, Chunyan Liu, Rong Fu
Förderung
- Tianjin Education Commission Research Project
Zitieren
APA
Peng, F., Gao, Y., Zhang, Z., Deng, L., Liu, H., Liang, X., Liu, C., & Fu, R. (2026). Shikonin Promotes Apoptosis in Multiple Myeloma Cells Through the PKM2 ‐ AMPK ‐ PGC1α Metabolic Axis. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.70384
Vancouver
Peng F, Gao Y, Zhang Z, Deng L, Liu H, Liang X, et al. Shikonin Promotes Apoptosis in Multiple Myeloma Cells Through the PKM2 ‐ AMPK ‐ PGC1α Metabolic Axis. Journal of Clinical Laboratory Analysis. 2026. doi:10.1002/jcla.70384
BibTeX
@article{Peng2026,
author = {Peng, Fengping and Gao, Yu and Zhang, Ziqi and Deng, Ling and Liu, Honglei and Liang, Xiaowei and Liu, Chunyan and Fu, Rong},
title = {Shikonin Promotes Apoptosis in Multiple Myeloma Cells Through the PKM2 ‐ AMPK ‐ PGC1α Metabolic Axis},
journal = {Journal of Clinical Laboratory Analysis},
year = {2026},
doi = {10.1002/jcla.70384}
}
EUVIMED